MedPath

AlphaGen Intelligence Corp Announces $195,000 Private Placement for Working Capital

3 months ago2 min read

Key Insights

  • AlphaGen Intelligence Corp announced a non-brokered private placement offering of up to 2,437,500 units at $0.08 per unit for gross proceeds of up to $195,000.

  • Each unit consists of one common share and one warrant exercisable at $0.12 for two years from issuance date.

  • The company plans to use net proceeds for general working capital purposes, with closing expected around May 16, 2025.

AlphaGen Intelligence Corp. (CSE: AIC | OTC: APETF | FSE: W4V) announced on May 8, 2025, a non-brokered private placement offering consisting of up to 2,437,500 units at $0.08 per unit, targeting gross proceeds of up to $195,000. The Vancouver-based company expects to close the offering on or about May 16, 2025.

Offering Structure and Terms

Each unit in the private placement consists of one common share and one whole share purchase warrant. The warrants are exercisable at $0.12 per share for a period of two years from the date of issuance. All securities issued under the offering will be subject to a statutory four-month and one-day hold period.
The company intends to use the net proceeds from the offering for general working capital purposes. The closing remains subject to satisfaction of customary conditions precedent, including receipt of all necessary regulatory approvals from the Canadian Securities Exchange.

Company Operations

AlphaGen Intelligence Corp. operates as a publicly traded company with a portfolio of assets spanning gaming, entertainment, eCommerce, and retail sectors. The company's operational units include Shape Immersive, described as a full-service metaverse studio that builds web3 gaming and virtual retail experiences for Fortune 500 companies through 3D, spatial computing, and game production.
The company also operates MANA, a SaaS solution and innovation lab that enables partner companies to enhance community engagement by launching their own gaming platforms. AlphaGen's client and partner roster includes RTFKT, Olympics, Red Bull, Intel, and TED.

Regulatory Considerations

The securities offered have not been registered under the United States Securities Act of 1933 and may not be offered or sold within the United States without proper registration or an available exemption. The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of the announcement.
CFO and Director Eli Dusenbury signed the announcement on behalf of the board of directors. The company noted that forward-looking statements in the release involve known and unknown risks, including the possibility that the offering may not close as expected or that proceeds may not be used as currently anticipated.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.